Chronic Lymphocytic Leukemia (CLL) MRD Panel By Flowcytometry

The CLL MRD Panel by Flow Cytometry is a test used to detect and monitor minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL). MRD refers to the persistence of a small number of cancer cells in the body after treatment, even when the patient appears to be in remission. By identifying and quantifying these residual cancer cells, this test helps assess the effectiveness of treatment and predict the likelihood of disease recurrence.